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Abs tract
Multicellular Tumour Spheroids (MTS) are a useful 
in vitro models of human cancer. Two cell lines - 
NB1-G and 1MR-32 - derived from two human 
neuroblastomas, were grown as MTS and were 
subjected to single, split and fractionated 
irradiation.
The NB1-G MTS line is radiosensitive, with low 
capacity for repair of sublethal damage, which 
indicated that NB1-G may be a suitable cell line to 
test the theoretical advantage of hyperfractionation.
The single dose response of 1MR-32 MTS, suggested 
that, intypically for neuroblastoma, 1MR-32 cells 
possessed a significant ’shoulder' on the cell 
survival curve.
Fractionated radiation regimes were designed to 
be theoretically isoeffective for damage to late 
responding normal tissues (calculated using the linear- 
quadratic mathematical model with g  = 3GY). The 
radiation responses of MTS were evaluated using the 
end-points of regrowth delay and 'proportion cured'
Regimens using smaller doses per fraction were 
found to be markedly more effective in causing damage 
to the NB1-G MTS, as assessed by either end-point.
The isoeffective regimens caused approximately 
equal damage to 1MR-32 soheroids also.
The findings were consistent with a substantial 
repair capacity for 1MR-32 MTS and implied that the 
well-known clinical heterogeneity of neuroblastoma 
might extend to its cellular radiobiology.
These experimental findings supoort the proposal that
hyperfractionation should be a therapeutically 
advantageous strategy in the treatment of tumours 
whose radiobiological properties are similar to those 
of the MTS neuroblastoma line NB1-G but not in the 
case of 1MR-32 MTS.
On the basis of these results, it seems plausible 
that hyperfractionation would not be a universally 
advantageous strategy, but one whose efficacy is 
likely to depend on being able to select aporopriate 
tumours for this form of treatment.
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Chapter 1
NEURQBL^LTQNA: THE CLINICAL PROBLEM 
Nature of Neuroblastoma
Neuroblastoma - Neuroblastoma Syrup a thi cum - 
originates from neural crest cells which normally 
give rise to sympathetic ganglia and the adrenal 
medulla. (1). It is the most primitive of the 
sympathetic nervous system tumours and is also 
the most common extracranial solid malignant 
tumour in childhood, which accounts forAICyc of 
paediatric cancers. (2, 3,4-, 5). Ihe tumours may 
occur anywhere from the superior cervical ganglia 
down the sympathetic chain to the bladder. The 
median age of diagnosis is 2-J years old and 9Ca 
of patients will be diagnosed within the first five 
years of life. (5).
Neuroblastoma is characterized by early 
dissemination and 7Cg of patients have tumour spread 
beyond the primary site at the time of diagnosis.
The sites of dissemination are the lymph nodes, bone 
marrow, bone, liver and skin, with the liver metastas 
mostly occuring in young infants ( <  6 months old) and 
the bone metastases more prevalent in older children.
(2,5).
Neuroblastomas often contain areas of differing 
degrees of maturation with the presence sometimes of 
fully mature ganglion cells.
Etiology of Neuroblastoma
The Etiology of Neuroblastoma is unknown, however, 
environmental factors are suggested by the fact that 
the tumour is uncommon in children in certain
geographical areas. (6).
It has been observed that there is a significantly 
reduced incidence of neuroblastoma in black children 
in tropical Africa in comparison with American black 
children, which suggests the presence of exogenous 
influences on the etiology. (2). In the United States 
of America it is less common in black children than 
in white children. (6).
In children with neuroblastoma, there seemed to 
be no association with immune deficiency syndrome 
or congenital defects. There is, however, an 
established link between neuroblastoma and foetal 
hydantoin syndrome i.e. women who took hydantoin 
anticonvulsants when pregnant. (3)»
Pathology of Neuroblastoma
Macroscopically, neuroblastoma appears encapsulated 
with poorly defined margins which infiltrate the 
surrounding tissue.
Microscopically, neuroblastoma is composed of small, 
round or slightly elongated cells with scant cytoplasm.
The first sign of differentiation is seen by the 
formation of rosette-like structures - a grouping of 
cells around a tangle of young nerve fibres, although 
these are not always present. (3,6).
Neuroblastoma cells have cytoplasmic structures 
consisting of neurofilaments, neurotubules and 
neurosecretory granules. The granules represent 
cytoplasmic accumulations of catecholamines. (3,6).
It is thought that coarse ultrastructural 
evaluation of undifferentiated neuroblastoma may have
prognostic value.
Clinical Manifestations.
The clinical manifestations of neuroblastoma 
often depend upon the location of the primary 
tumour. Neuroblastoma tumour tissue can occur 
anywhere that sympathetic neural tissue normally 
occurs. In more than 50% of cases, a primary 
tumour is found in the Retroperitoneal region which 
arises in the adrenal medulla or a sympathetic 
ganglion. (5).
In some tumours, there is extension through to 
the spine and children may present with signs of 
spinal cord comoression.
Late recognition of the intraspinal component 
has resulted in permanent paraplegia, which is 
unfortunate because patients with dumb-bell shaped 
neuroblastoma have a very good chance of survival. (3,5) 
Horner's Syndrome is the result of an involvement 
of the cervical sympathetic ganglion and is 
associated with enopthalmus, ptosis of the upoer 
eyelid, slight elevation of the lower lid and 
constriction of the pupil. (3)*
When neuroblastoma arises in the opthalmic 
sympathetic nerve, Heterochromia iridis - a difference 
in the colour between the two iridis - may result. (3,5) • 
A particular pattern of spread peculiar to neuroblastoma 
is the association of orbital and liver metastases.
Meningeal or Intercerebral metastases may occur 
but are rare. (6) .
Biochemical Features
Increased levels of Catecholamines and their 
metabolites are found in the urine o f > 9 0 %  of
neuroblastoma patients. This is thought to be due 
to their increased production or to their defective 
storage within the tumour cells. (6).
The most frequently assayed urinary catecholamines 
are Vanillymandelic Acid (VMA) and Homovanillic Acid 
(HVA).
VMA is elevated in the urine of 75 - 96% of 
neuroblastoma patients and an HVA elevation is found 
in 68 - 95%* (3,6). The VMA/EVA ratio has been 
shown to have prognostic significance with the most 
favourable outcome associated with VMA/HVA ratios 
greater than or equal to 1.5 (3). A patient 
occasionally shows no sign of increased catecholamines 
although a periodic assay of urinary VMA/HVA levels 
have proved to be a good prognostic test with good 
reliability (80 - 90%) (3).
The amount of HVA does not matter to prognosis, 
although the higher the level of VMA, the better the 
prognosis . (3)•
Increased levels of HVA and VMA have also been 
found in plasma. Plasma Carcinoembryonic Antigen(CEA) 
levels are increased in a number of malignant and non- 
malignant diseases. (3,6).
Ccmolement levels increase and fluctuate during the 
course of neuroblastoma, they often rise with 
recurrence but decrease if the disease becomes 
terminal. (3)•
Increased levels of Neuron-Specific-Enolase (NSE) 
have also been found in neuroblastoma tissue, although 
it is not neuroblastoma specific.
Gene Amnlification t -^ has been demonstrated by
Kohl et al that there are two metaphase chromosome 
anomalies in many human neuroblastoma cell lines. (7)* 
These are long, non-banding homogeneously staining 
regions (HSR's) and small, paired chromatin bodies 
known as Double Minutes (DM’s). It is thought that 
the H S R ’s and DM's of human tumours are likely to be 
manifestations of amplified genee.
The amplification process is associated with the 
transposition of the sequences involved from the 
short arm of chromosome two to the long arm of 
chromosome one. The frequent occurrence of DM's 
and HSR's in neuroblastoma tumours and cell lines 
indicated that amplification was a general property. (7). 
Biedler et al speculated that the H S R ’s were in some 
way functionally involved in the excessive production 
of one or more proteins specific to the malignant 
neuronal cells. (8). Kohl et al suggested that the 
commonly amplified sequence was representative of a 
gene - N-MYC - whose production was necessary for the 
proliferation of neuroblastoma tumour cells. (7).
Erodeur et al have shown that N-MYC is amplified 
in >90°-^ of human neuroblastoma cell lines irrespective 
of the cytogenetic form of the amplified D N A . The 
amplification, however, is only found in 38% of primary 
tumours and the reasons for this are unknown. (9)*
It has been demonstrated by Gilbert et al that one 
or more genes on chromosome lp were involved in 
neuroblast transformation and that amplification of 
certain one genes contribute to the ability of a 
tumour to metastasize. (10).
I
11
Staging and Diagnosis
The most widely used staging system for
neuroblastoma was devised by Evans et al in 1971.
(2,3,5,6).
Stage 1 tumour is confined to organ
or structure of origin.
Stage 11 tumour extending in continuity
beyond the organ or structure of 
origin but not crossing the 
midline. Regional lymph nodes 
may be involved.
Stage 111 tumour extending in continuity
beyond midline. Regional lymph 
nodes may be involved bilaterally.
Stage IV remote disease involving skeleton,
parenchymatous soft tissue or 
distant lymph node grouos.
Stage 1V-S otherwise classified as having
Stage 1 or 11 but with remote 
disease confined to one or more of 
the following sites - liver, skin 
or bone marrow.
Most patients with this stage are 
less than one year of age.
Suontaneous regression occurs. (2). 
There are biolosical differences between Stage IV
and 1V-S e.g. there are increased serum ferritin levels 
in Stage 1V_ but not Stage 1V-S . (2,3,6). Increased 
serum ferritin levels are associated with an 
unfavourable prognosis. (3).
Prognostic Factors.
The prognosis of neuroblastoma is affected by 
the following factors
(a ) Age of the patient at the time of diagnosis. 
Infants who remain free of neuroblastoma, for one year 
are usually cured but older children have been known 
to experience recurrences many years after initial 
diagnosis. (3) •
Children less than one year and older than six 
years do better than children between the ages of 
one and six.
Children older than six have a less aggressive 
disease and may live 5 years or longer before 
succumbing to their illness. (6).
(b ) Clinical stage at the time of diagnosis.
This is the single most important prognostic factor 
and together with the patient's age are the two 
independent variables which are of the greatest 
prognostic significance. (3,5,6).
Patients with Stages 1 and 11 generally have good 
prognosis. Few children with Stages 111 and IV 
neuroblastoma - regional or widespread metastatic 
disease - survive disease free for more than two years. 
For all stage of disease beyond localized, completely 
excised tumours, the infant of less than one year 
has a significantly better remission rate and survival 
rate than the older child of equivalent stage. (5)
(c ) Localization of Primary Tumour.
Children with abdominal primary tumours have the worst 
prognosis, and in this group, those with nonadrenal 
primaries have a better prognosis than
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those whose tumours originate from the adrenal glands.
(1,6).
(d) Lymphocyte Count
Spontaneous remission and maturation have been 
attributed to, in part, host immune defense 
mechanisms. (3,6). Lymphocytes of most patients 
cured of neuroblastoma and those which have active 
disease, have been known to inhibit the growth of 
neuroblastoma cells in tissue culture - a 
phenomenon not seen in lymphocytes from control 
subjects. This cytotoxicity appears to be mediated 
by T-cells. (3,6).
Other factors involved in the prognosis of neuro­
blastoma include site of metastases, lymph node 
involvement and the histological make-up of the 
tumour i.e. degree of differentiation. (1,5,6).
The presence of tumour in regional lymph nodes 
markedly alters the prognosis in these patients 
and they have a clinical course much the same as the 
child with more widely disseminated tumour. (5)*
Vaage et al summed up the most favourable prognostic 
circumstances:-
(1) tumour diagnosed within the first 
three months of life..
(2) tumour localized in cervicotheracic 
region.
(3) clinical Stage 1
(4) tumour histologically well differentiated
a n d (5) normalization of levels of post-operatively
excreted catecholamine derivatives (VMA and 
H V A ) (1) .
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Present Treatment Methods.
Therapy of neuroblastoma is often difficult to 
evaluate because of the tumours unpredictable course 
and the lack of uniform criteria for defining 
treatment response.
Before surgery, however, complete evaluation for 
metastatic disease should be carried out with 
computerized axial tomography (CAT) of the abdomen, 
liver scan and bone scan. Urinary catecholamine 
levels should be obtained.
Surgery
Where at all possible, total surgical removal of 
Stage 1^ and 11 should be undertaken. The two years 
disease free survival of this group varies from 84?^ 
when complete resection is performed, to 63?i when 
only partial resection is possible. There is no 
evidence to suggest that further therapy improves 
survival even when macroscopic disease is left 
behind. (5,6).
The exact role of surgery in Stage 111 and IV 
tumours has yet to be defined, although it has been 
shown that there is no improvement in overall 
survival using debulking surgery for Stage IV patients.
When surgery is performed following other treatment, 
however, the survival period is longer than if no 
surgery was used. (6).
Radiation Treatment
Neuroblastoma is a radiosensitive tumour, but the 
exact role of radiation therapy in i t ’s treatment still 
remains to be defined.
Radiation therapy does not seem to benefit patients
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with Stage 1 and 11 disease, even when macroscopic 
tumour remains following surgery. (3,6).
It is normal to irradiate residual Stage 111 
tumour after surgery or even before to reduce tumour 
size. It is not known whether radiation improves 
survival in these cases. (3,6)
Radiation therapy clearly plays a role in the 
palliative treatment of patients with Stage IV 
disease. (6).
Chemotherapy
Chemotherapy is used for the majority of patients 
with disseminated neuroblastoma. The variety of 
drugs and drug combinations that have become available 
over the past 20 years have significantly increased 
the tumour response rate (3,6).
Combination chemotherapy with cyclophosphamide, 
vincristine and adriamycin in two and three drug 
combinations has not resulted in a definite increase 
in the complete remission rate.
Since cisplatin and VM-26 were added to 
cyclophosphamide and vincristine, however, there seems 
to have been a difference observed in recent years.
It has been concluded, therefore, that at the present 
there has been no confirmed increase in the median 
survival of children with metastatic neuroblastoma 
(Evans Stage 111 and IV) over the past 30 years. (11).
Carli et al looked at 26 different chemotherapeutic 
drugs used as single agents and found that only the 
6 named below achieved a clinical response in at least
20% of the patients.
Cyclophosphamide. Cis-platinum.
Vincristine. VM-26.
Adriamycin. Peptichemo. (5,6).
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There is some evidence that aggressive combination 
chemotherapy may improve the survival rate in older 
children and adults with metastatic disease.
Nitschke et al treated 33 children with Stage IV 
neuroblastoma with intensive chemotherapy. The 
drugs used were Cyclophosphamide, Vincristine, Papaverine 
and Trifluoro-methyl-2-deoxyridin. The therapeutic
value of the four drug combination was limited due 
to side-effects related to myelosuppression which 
resulted in severe complications. (12).
Voute et al used a four drug schedule of Vincristine, 
Prednisolone, Cycloohosphamide and Methotrexate.
Complete remissions were achieved but could not be 
maintained. (13).
Finklestein et al looked at 104 Stage IV 
neuroblastoma patients, using a triple drug regimen 
of Cyclophosphamide, Imidazole, Carboxamide and 
Vincristine, and a similar regimen plus Aariamycin.
They found no significant difference in the median 
survival observed in children with Stage IV 
metastatic neuroblastoma, although overall survival 
significantly improved. It was found that the 
children under one and older than six at the time 
of diagnosis, had >40°^ greater. chance of enjoying 
prolonged tumour-free survival. (14).
If systemic treatment is needed in certain stage 
Tv - S patients, gentle chemotherapy is often very 
successful. (2).
Late Fffects of Treatment 
Radiation Therapy
(a) Skeletal Effects.
Irradiation of growing bone reduces growth rate 
and causes early fusion of the epiphyses.
(b) Soft Tissue Effects.
Failure of muscle development.
(c) Endocrine Organ Effects.
Children treated in the early years were irradiated 
throughout the whole abdomen and so the girls' ovaries 
and the boys' testes received the total dose of 
radiation. Most of the children had complete ovarian/ 
testicular failure and required hormonal replacement 
for pubertal development to take place.
Children with neuroblastoma in the neck had their 
Thyroid Gland irradiated and the thyroid dysfunction 
that resulted was compensated with increased levels 
of thyroid stimulating hormone.
Chemotherapy
Since treatment with cytotoxic drugs is fairly 
recent, not much is known about the late effects of
18
chemotherapy.
Limitations of Chemotherapy
The effectiveness of chemotherapy is compromised
when cells are not proliferating or when tumour
growth kinetics are almost zero, as seen in the necrotic
centre. Cells in less vascularised areas will only
be exposed to lower concentrations of the
chemotherapeutic agent. (. 4).
The response rates to drugs in children under two
years of age at diagnosis are usually as high as 60;i
but the cure rates may be lO'k to 25°i with
disseminated disease. (4).
Combination Therapy
Cue to the immediate enhancement of radiation by 
certain of the cytotoxic agents, one might expect
that there will be greater late effects although
there is only limited evidence of this. (2)
Neuroblastoma patients d o n ’t usually have both
treatments now.
Radiochemotherapeutic treatment of minimal
residual disease in neuroblastoma was studied by
Zucker et a l . (15)
In the low risk patients, the early and late
hazards of therapy were found to be higher than the
benefits and Zucker concluded that even
radiotherapy after partial removal and chemotherapy
in Stage 11 patients was questionable.
Proposals for New Treatment.
Due to the limited success in the treatment
of patients with disseminated neuroblastoma, several
new experimental aporoaches are being investigated.
This section will attempt to summarize what has been
19
done.
Antibody Targeted Radiotherapy
A quick and accurate diagnosis of malignant 
disease is essential, in order that the appropriate 
treatment may commence without delay.
Most malignancies can be diagnosed from the 
clinical picture and the results from histopathological 
and cytological analysis, although neuroblastoma 
can be difficult to differentiate from other small 
blue round cell tumours. (16).
Monoclonal antibodies were proposed as 
good diagnostic and therapeutic tools in 1982 and 
have a high degree of tumour specificity - not absolute 
tumour specificity but orerational specificity - and 
availability. (16,17).
Antibodies which do exist are used for in vitro 
diagnosis of tumour type and in vivo detection of 
metastatic spread of tumour. (1?). If such 
antibodies can be radiolabelled without any loss of 
immunologic specificity, they may be able to deliver 
cytotoxic amounts of radiation, cytotoxic drugs or 
toxins to the tumour. (18,19).
In order to minimize normal tissue irradiation, 
target cell specificity and a high extraction 
co-efficient are necessary with any radionuclide.(18). 
Other factors influencing i t ’s applicability are 
tumour cell retention time and the rate of catabolized 
radionuclide. (18).
The choice of radionuclide for antibody mediated
radiotherapy is a difficult problem. Long range B - particle 
I 'i
emitters like I have been used so far but short range
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- particle emitters like At are under consideration.
I1’or short - range emitters, it is important that every 
cell he targeted which may not he possible with single 
antibodies due to reported antigenic heterogeneity in 
some tumours.
In order to overcome heterogeneity in antigen 
expression seen in neuroblastoma, it is necessary 
to use a panel of monoclonal antibodies and 
currently there are 11 different anti-neural 
antibodies in use to assist in the diagnosis of 
neuroblastoma. (16,17). Such heterogeneity could 
be due to the fact that cells blocked at different 
stages of maturation exnress different profiles of 
introcellular or cell membrane antigens. There is 
an occasional cross-reactivity, the mechanism for 
which is unknown. (16).
Kemshead et al used a panel of monoclonal 
antibodies to differentiate between leukaemia, 
lymphoblastic lymphoma and neuroblastoma. The panel 
of monoclonal antibodies offered a rapid and accurate 
adjunct to conventional techniques in the diagnosis 
of neuroblastoma. (16).
Cheung et al used 3 different monoclonal antibodies 
which were cytotoxic to neuroblastoma in the presence 
of complement. All identified neuroblastoma in 
patient specimens and, using indirect immunofluorescence, 
they could reproducibly detect <C.1/j tumour cells 
seeded in bone marrow cells. (19).
Studies using monoclonal antibodies conjugated with
12b 1b1low doses of either I or y 1 have demonstrated the 
possibility of targeting antibodies to primary and
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metastatic tumour sites in patients with neuroblastoma.
UJ13A is a monoclonal antibody which is known to 
bind to human neuroblastoma cells. Preclinical 
studies have demonstrated that radiolabelled UJ13A 
is taken up into human neuroblastoma xenografts 
established in nude mice, although no antibody 
uptake was recorded when experiments were repeated 
with an antibody known not to bind to human 
neuroblastoma. The levels of the radio-labelled 
antibody conjugate fell more rapidly in mouse blood 
and organs, than in tumour tissue. (17,20).
Before antibody-mediated radiotherapy can be 
used to i t ’s full capacity, certain objectives need 
to be achieved e.g. preservation of immunologic 
specificity after labelling, elimination of cross­
reactivity with normal tissue antigens and the use 
of monoclonal antibodies of human rether than murine 
origin. (18).
MIBG - Targeted Radiotherapy
The compound Meta-Iodobenzylguanidine (MIBG) is 
an analogue of a precursor of epinephrine and nor­
epinephrine and so had a strong affinity for the 
adrenal medulla and adrenergic storage vesicles.(17, 21).
MBG follows the metabolic pathway of norepinephrine 
and tissues which have reservoirs of hormone retain 
norepinephrine and norepinephrine-like compounds e.g.
M I B G .
Neuroblastoma tumour cells can synthesize and 
store catecholamines. (21,22).
Radio iodinated MIBG allows safe, non invasive, 
sensitive and specific scintigraphic location of
neuroblastoma tumour cells (22) and is useful in 
locating primary tumour as well as residual, recurrent 
or metastatic disease. (21).
In oatients with bone marrow metastases, systemic 
uptake may lead to a high dose being delivered to 
bone marrow stem cells. (21). Harvested bone marrow 
may be cleaned using specific antibodies and 
reinfused after therapy to circumvent the bone marrow 
toxicity.
The therapeutic possibilities afforded by ,3,I-MIEG 
may give a new role for radiotherapy in the treatment 
of children with neuroblastoma.
Total Body Irradiation and Bone Marrow Rescue
Some of the newer experimental approaches in the 
treatment of oatients with disseminated neuroblastoma 
include Total Body Irradiation (TBI), which is used 
as a systemic therapeutic agent.
Total Body Irradiation (TBI) with bone marrow 
rescue is being used increasingly in the management 
of children with first or second remission. (23).
TBI as a preparation for Bone Marrow Transplant (BMT) 
has three functions.
(1) Immune Suppression
This is essential for the graft to ’tak e ’
(2) Elimination of Malignant Cells from the body 
This seems to be more successful if the number of
tumour cells has been reduced by previous intensive 
treatments.
(3) Bone Marrow Ablation
There is some evidence that grafted bone marrow 
can only be successfully established if 'space' in 
the marrow cavity is made by a huge deletion of
haemopoietic elements by TBI. (23).
Wheldon et al looked at log cell kill after low 
and high dose TBI on human neuroblastoma cells 
in vitro. (2). They predicted that low dose TBI 
achieved only modest cell kill but high dose TBI 
with marrow rescue could reduce the number of 
clonogenic cells by a factor of 10 - 1(r ,
without severe side-effects.
Bone marrow stem cell toxicity is frequently the 
dose-limiting factor with conventional cytotoxic 
drug and/or radiation therapy. (17,25,26). This 
can be overcome by using autologous or allogenic 
bone marrow rescue. Bone marrow contamination 
by metastases is often present at diagnosis which 
may limit the availability of uncontaminated marrow 
for haemopoietic reconstitution. (17,26,27).
Several techniques have been developed to ablate 
tumour cells from harvested bone marrow to be used 
for autologous bone marrow e .m . treatment of bone 
marrow with drugs or physical procedures relying 
on differential centrifugation.
Immunological procedures include coating malignant 
cells with antibody for opsonisation, treating bone 
marrow with antibody and complement or with 
antibodies to which either drugs or toxins have been 
attached. (17)•
The use of fluorescence activated cell sorting 
for cleansing tumour cells from bone marrow 
experimentally has produced good results but it is too 
slow. (17)•
Kemshead et al developed an alternative approach
to fluorescent sorting - the use of a Magnetic 
Separation procedure. (17,26,28).
This method removes neuroblastoma cells from 
bone marrow by means of monoclonal antibodies 
conjugated to magnetic polystyrene microspheres.
The separation of the cells is on the basis of their 
iron content and it is possible now to target 
microspheres (using Magnetite) to any type of cell 
using monoclonal antibodies. (17,26,28).
Using the magnetic separation device, it is 
possible to purge approximately 5 x 10^ bone marrow 
cells of at least 99.9% of tumour cells in 3 hours. (17).
This method is advantageous because it allows rapid 
estimation of tumour cell removal from the ’magnetic 
negative* fraction and testing and absorption of 
complement is not required. (26).
The indirect method of attaching beads to tumour 
cells using monoclonal antibodies and anti-mouse 
Immunoglobulin has several advantages over a direct 
system where microspheres are coated with monoclonal 
antibodies. It is more efficient and economical; 
the separation technique depletes tumour cells from 
bone marrow to a level of at least 1:1000 and 1:10000 
nucleated cells; the use of the technique for T-cell 
depletions from bone marrow to be used for allogenic 
transplantation is being investigated and the new 
beads require less anti-mouse Immunoglobulin to coat 
their surface. (26).
Kemshead et al looked at new M450 magnetic beads 
and discovered them to be more effective than the older 
K330 beads. (28). The new beads have hydroxyl groups
f
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on the surface, allowing monoclonal antibodies, 
anti-mouse immunoglobulin or other antibody 
binding molecules to be covalently linked to the 
surface of the microspheres.
Tumour cell contamination of harvested bone 
marrow from neuroblastoma patients for use in 
autologous marrow transplantation may adversely 
affect patient survival. It is still not known 
whether tumour cells which are re-infused are 
clonogenic and what numbers of viable cells would 
be necessary for re-establishment of the disease.
Reynolds et al looked at two methods for 
sensitive detection of neuroblastoma cells in 
bone marrow. (29). The first method was for use 
in model systems. The viable neuroblastoma cells 
were premarked with the LNA stain Koechst 333^2 (K34-2) 
and seeded into normal marrow for purging experiments.
The fluorescence of E3R2 stained cells, allowed 
detection of one E3E2 stained cell in one million 
marrow cells.
Counterstaining the mixture with trypan blue, 
reduced the E3E2 fluorescence in non-viable cells, 
therefore, limiting the detection to viable cells only.
The second method could be used in model systems 
or clinical bone marrow specimens. It relied on 
the specific staining of neuroblastoma cells with an 
antiserum to Neuron Specific Enolase (NSE) and/or with 
anti-neuroblastoma monoclonal antibodies. If the 
haemopoietic cells were removed from the marrow before 
staining i.e. enriching the neuroblastoma cells in the 
sample, it allowed detection of neuroblastoma cells at
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1:100,000 using NSE alone.
In spite of all the recent advances that have 
been made in chemotherapy and monoclonal antibodies, 
the therapy of neuroblastoma still remains 
unsatisfactory and in order to determine how treatment • 
would best be improved by the addition of 
radiotherapy which is believed to be an effective 
agent, further studies of the radiobiology of 
neuroblastoma are very important.
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Title
RADIOBIOLOGICAL CCNSITSRATIQMS
It has been known for a long time that 
reproduction is the most radiation sensitive 
activity of mammalion cells. (1,2,4).
Irradiation, at dose levels which have a high 
probability of reproductive sterilization, has no 
effect upon cellular metabolism or on the ability 
of specialised cells to synthesize tissue-specific 
proteins. Radiation sterilized cells with a few 
exceptions (e.g. some small lymphocytes, oocytes) 
stay physically and biochemically competent until 
cell division is attempted and cell death results.
This is an indication that radiation-induced 
functional impairment of tissue is mediated through 
the reproductive sterilization of proliferative 
cells. (2).
For most tissues, it is thought that physiological 
functional impairment is a direct result of the loss 
of reproductive integrity by the proliferative cells, 
especially the clonogenic cells of the tissue, 
concerned i.e. a failure of radiation-sterilized 
clonogenic cells to keep pace with the need to replace 
functional cells which are being lost from the tissue 
at a characteristic rate. The loss of this ability 
as a function of the radiation dose is described by 
the Dose Survival Curve.(3)-
The deposition of radiant energy and the infliction 
of radiochemical injury are random events. The dose- 
response relationship for cell killing is essentially
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exponential i.e. for a given dose increment, the 
same proportion. not the same number of cells is 
killed. (17).
The relationship between the radiation dose 
absorbed and the proportion of cells which 'survive' 
can be seen in a cell survival curve, which is a 
special form of dose-effect curve, and is based on 
viable cell counting i.e. the counting of 
colonies originating from single cells. The ability 
of a single cell to grow into a large colony is proof 
that it has retained it's reproductive integrity.
Mammalian cell survival curves are usually 
presented with dose plotted on the linear scale and 
surviving fractions on a logarithmic scale.
At low doses of radiation, there is an initial 
shoulder which becomes straight or almost straight at
high doses on the semi-logarithmic plot. The slope is
expressed in terms of the dose required to reduce 
the number of clonogenic cells by the factor of e , 
i.e. to 37% cf their previous value - called the 37% 
dose slope and is designated Do.
The extrapolation number - n - is found by 
extrapolating the straight portion of the survival
curve until it cuts the 'surviving fraction axis'.
The extrapolation number is important because it is 
a measure of the initial shoulder. (3)«
The intercept of the extrapolated curve with the 
1CC% survival level is called Dq - the quasithreshold 
dos e .
.Dq and n are interrelated because both are a 
measuie of shoulder size (Da is not a threshold but
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a mathematical term) (17).
3s the dose rote of irradiation is decreased, 
the efficiency of cell killing per Gray has been 
shown experimentally to decrease too, i.e. the 
’effective D0 ’ increases (17).
Models for estimating equal effects when 
different fractionation schedules are used, have 
been evolved to the stage of using reasonable dose- 
response curves to represent the biological effect 
of each fraction, plus a separate time factor.
There are three dose-resoonse formulae which are 
commonly used:
(1) The Linear Quadratic Model.
(2) The Multi-target Model (provided 
it has an initial siore 
superimposed i.e. 2 component 
slooe)
(3) The Repair - Misreoair Model (16)
The Linear Quadratic Model
The L-"' Model is very useful for describing the 
in vitro survival curves of human tumour cell lines.
It offers valid approximations for all clinically used 
doses, has only 2 parameters to be determined and is 
very easy to use in practical applications (16).
The L-Q Model assumes that the sterilization of 
clonogenic ’target cells' in the tissue during 
radiation is the cause of the observed effects. The 
target cells have a dose-response curve for 
clonogenic survival which is linear quadratic in dose (29).
From the evidence obtained from single hit killing 
by high LIT radiation, it wa3 suggested that the
inactivation of a cellular target, should only 
require the passing of one densely ionizing particle 
through the ENA double strand. This would mean 
that the ’high L E T ’ components of neutron 
irradiation would cause lethal lesions in direct 
proportion to the dose. The term attributed to this 
was ©<- thus making the^D portion of the equation.
With low LET radiation then, lesions would only 
accumulate as the square of the dose i.e. one lesion
requires energy deposition by 2 independent electrons 
within the target volume. The sublesions caused 
must interact to cause lethal lesions. This was 
termed BD^ in the equation.
The entire equation i s :-
Inf = - ( p< D + BD2 ) (13)
The Multitarget Model
The Multitarget, two component (TC) model 
requires 2 independent parameters - D0 and n.
It originates from the theory that a cell contains 
n targets - all alike - and if all are inactivated, 
the cell cannot proliferate. Hits are considered 
to be distributed randomly in uniformly irradiated 
homogenous cell populations. (17,18,30).
If, however, one of the targets is not 
inactivated, the cell is still capable of 
proliferation. (13)*
The Reoair/Misrepair Model
This hypothesis suggests that the surviving 
fraction of cells in a mutagen-treated population 
is proportional to the number of potentially lethal 
lesions that are not repaired (30).
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It is thought that, over a certain range of dose 
rate, physical or chemical lesions from statistically 
independent charged particle tracks do not interact.
So, only lesions from singly charged particle tracks 
need to be considered in the physical and chemical 
time domains. These lesions produce longer lived 
biological lesions, some of which are enzymatically 
repaired and some interact with other lesions.
The Model, therefore, has 2 parts
(1) deals with repair and/or interaction with other 
biological lesions and (2) deals with the 
production of biological lesions through evolution 
of the physical and then the chemical lesions. (31).
The cell survival models discussed so far, were 
designed on the assumption that a relatively 
insensitive region to a dose effect curve signifies 
the requirement for an accumulation of damaging events, 
if the end - point is to be achieved. It has been 
suggested that, if cells survive by the accumulation 
of damage, they must surely contain a repair mechanism 
which becomes less effective as the dose or the number 
of incipiently lethal lesions increases, until it 
ceases to operate. (13).
The initial slope of the dose-respcnse curve is of 
major importance because, at lower doses (2 Grays or 
less) repair processes are at their most efficient, 
so the ’initial’ slope represents the fullest 
expression of repair.
Two distinct mechanisms of cell killing are thought 
to produce a shouldered cell survival curve - one 
being single hit killing (a single lethal injory) and
the other being an accumulation of sufficient 
sublethal lesions whose interaction cause death. (17,18)
As the dose increases, presence of a shoulder on 
the survival curve of most mammation cells is an 
indication that the efficiency of cell killing per 
Gray increases (up to a certain limit depending upon 
cell type).
The manifestation of a shoulder on a survival curve 
was assumed to be evidence that radiation - induced 
damage must accumulate within the cell before a final 
event could prove lethal. The damage which was 
assumed - leaving the cell still viable - became known 
as ’sublethal damage’ and the recovery which restored 
the cells’ capacity to accumulate sublethal damage was 
known as the recovery (or repair of) sublethal damage. 
Repair of Sublethal Eamage/Elkind Recovery.
Sublethal damage can be repaired in a matter of hours 
unless additional sublethal damage is added e.g. from 
a second dose which will interact to produce lethal 
damage.
It was discovered, after X-rays started to get used 
clinically, that their biological effectiveness was 
usually lowered when low dose rates were used or when 
the total dose was delivered in fractions. It was the 
investigation into dose fractionation which helped 
the discovery of the sparing effect observed when a 
reduction in dose rate was employed. It was 
demonstrated that it was linked with the 
manifestation of shoulders in survival curves.(18). 
Elkind and Sutton completed a series of experiments 
on mamma'lion cells in which two sufficiently large
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radiation doses uere given, several hours apart.
The shoulder on the first survival curve was 
reproduced on the second survival curve. The first 
dose reduced survival to the terminal exponential 
region of the survival curve where all surviving cells 
coulc. be considered to have accumulated one less than 
the lethal number of hits. The full recovery of the 
shoulder on the second dose survival curves was an 
indication that all the sublethal damage had been 
repaired in the interval between the two doses 
(11,17,'4 )
The method employed for investigating Elkind 
Recovery involves the use of solit dose radiations and
measures the survival as a function of time between
two doses.
Elkind and Sutton discovered that, as the time 
between doses was increased, survival increased until 
a maximum was reached after two hours recovery.
When the length of recovery interval was increased 
further, the survival fell to a minimum and then rose
to a olateau level. This was explained by taking
into account the partial synchrony imposed on a 
heterogeneous cell population after the first radiation 
dose. The cells which survived the first dose were 
those in the more resistant phases and the surviving 
population would be partially synchronized. (10,13 )
Bryant et al discovered that the speed of recovery 
in algal cells was dependent upon the partial pressure 
of oxygen i.e. Elkind recovery was an energy 
dependent process (13)
The actual nature of sublethal damage and it's
36
repair are not yet fully understood. (19).
Repair can be suppressed by exposure of cells 
to metabolic inhibitors e.g. cyanide, severe 
hypoxia or cold, before and after irradiation.
So, the increased radio-resistance of hypoxic cells 
in vivo could be oartly offset, in fractionated 
treatment, by their reduced capacity for repair 
of sublethal damage. (17,20).
Elkind demonstrated that there was a close 
connection between radiation damage/repair and 
the normal synthetic processes of cells. (23).
It is generally accepted that one cannot associate 
all DNA damage e.g. all strand breaks, with cell 
killing and one cannot connect all DNA repair with 
cell repair.
Efficient strand rejoining occurs in cells which 
will stop dividing and eventually lyse, indicating 
that the enzymatic machinery of cells consists of 
small, multiple replicated molecules which are 
therefore not high in the hierarchy of radiation - 
sensitive targets. (22).
In conclusion then, it is thought that DNA damage 
is the primary cause of cell killing and repair of 
DNA damage is causally related'to cell repair.
The molecular and cellular damage/repair processes 
take place, in and around the replisome i.e. where 
DNA undergoes the sequential transition from a super 
helix of a single duplex to two superhelixes of 
replicated DNA. (22).
The imoortance of sublethal damage repair for 
radiotherapy is that, within certain limits, the total
dose required to achieve a certain level of cell 
killing increases as the number of dose fractions 
increases.
Lethal Damage
This type of damage is irrepairable, irreversible 
and leads to death.
Potentially Lethal Damage
This is radiation damage which could cause cell 
death under some post irradiation culture conditions 
but not in others e.g. nutritional deprivation, 
low temperatures and inhibition of protein synthesis 
by cycloheximide, all of which prevent the progress 
of cells through the division cycle (3,17)
Clinical Radioresistance
The extent of radiation damage observed in tissue 
is dependant upon several factors, including tissue 
responsiveness to radiation, and it is knov;n that 
there are multiple biological factors involved in 
clinical radioresponsiveness.
The operational definition of ’Tumour Radioresistan 
is: ’A tumour is clinically radioresistant if it
regrows within the irradiated region, regardless of 
it's rate of regression'. (6)
Causes of Clinical Radioresistance
Tumour Related Factors
(a) Lumber of clonogenic cells
A clonogenic cell is one which is capable of 
regenerating the tumour and must belong to the stem 
cell compartment or be capable of being recruited back 
into the pool. Since the killing of tumour cells is 
random, tumours with a large number of clonogens are
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more difficult to destroy thsn tumours with a 
few clonogens of similar radio-sensitivity. It is 
impossible to quantitate the number of clonogens in 
human tumours and so one cannot predict
radioresistance based on a large number of clonogens.(5)
IVhen a homogenous group of tumours are exposed 
to graded irradiation doses, a Tumour Control 
Probability curve (TCP) is produced, which implies 
that tumour populations are heterogeneous and sub 
populations of studied tumours vary in their 
'radioresistance'.(5).
(b ) Evpoxia
As solid tumours grow, the tumour vasculature 
often fails to keep up with the increase in the number 
of tumour cells. As cells become more than-^180 
microns distant from the nearest capillary, they become 
hyooxic (oxygen deficient) and die producing a 
necrotic centre in the tumour. Tumours do not have 
to be large and bulky or necrotic to contain hypoxic
For ionizing radiation, the oxygenation status 
of the cells is considered to be an important factor 
in determining response. Hypoxic cells are thought 
to be three times less sensitive than oxygenated cells 
to X-ray radiation.(3>17)
The shape of mammalion cell survival curves after 
exposure to X-rays in the presence and absence of 
oxygen is seen to be the same. The difference is the 
magnitude of the dose required to cause a given 
degree of biological damage. The ratio of hyooxic 
to aerated doses reauired to produce the same
:
ce11s .
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biological effect is the same at all survival 
levels and the ratio is known as the ’Oxygen 
Enhancement Ratio’. (3,17).
(c ) Tumour Kinetics
There have been many theories put forward to 
explain the Phenomenon of tumour recurrence, 
including rapidly proliferating tumours which can 
significantly repopulate during a conventional 
treatment regimen and slowly growing tumours 
which may be radioresistant due to poor 
redistribution throughout the division cycle during 
dose fractions, to quote only two.
(d ) Intrinsic Radioresistance
This is defined as ’cellular radioresistance’ 
manifested by asynchronous, well oxygenated 
populations of tumour cells in vitro. (6).
There are two kinds demonstrated:
(1) is associated with a large shoulder on a 
radiation cell survival curve indicating a capacity 
for 'Elkind type repair’, and (2) is associated 
with plateau phase cultures with clinical 
resistance which have an increased ability to repair 
Potentially Lethal Damage.
It is now agreed that the initial slope of a cell 
survival curve at 2 Gray and lower is the region 
of interest. (26,27,32). The ’final slopes' 
represented by Do refer to a minority of cells and 
are largely irrelevant in fractionated radiotherapy.
Since n and D 0are the currently used parameters 
and are calculated from the high dose portion of the 
graph, they cannot be used to define the low dose
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radiosensitivity in vitro of a cell line whose 
survival curve has an initial shoulder.
A single model free parameter, the mean 
activation dose - D - is the area under the survival 
curve and has been suggested for the characterization 
of human tumour cell line radiosensitivity at 
clinically relevant doses.
r depend- upon the initial portion of the in vitro
survival curve end it has been shown that the
parameters S p , D and (p{D + B D ^ ) are the most suitable
/
for the characterization of human cell radiosensitivity. 
(27,28).
Fertil and Malaise looked at in vitro survival 
curves (low dose portion only) at 2 Gray (S2) and 
established a correlation between S2 and the 
clinical radioresponsiveness of the group from which 
the tumours were derived. (5,26). This was confirmed 
by Deacon et al who demonstrated that 2 Gray was the 
optimum dose level to compare the biological data 
with clinical radioresponsiveness. (26).
The observed differences in in vitro 
radiosensitivity as a function of the histology of 
the tumour, argue strongly for the role of certain 
intracellular factors in clinical responsiveness (5,26).
Clinical responsiveness is known to be linked to 
the histology of the tumour and it is known that 
intrinsic radioresponsiveness varies from one 
histological cell type to another. (5,26,27,28).
Weichselbaum completed studies on radiosensitivity 
and radiation damage repair in human cell lines.
He discovered that some radio-incurable tumour produced
41
cell lines which possessed the ability to repair 
potentially lethal damage in plateau phase 
cultures.
The cell lines found to be most efficient at 
potentially lethal damage repair had been derived 
from patients who had failed clinical radiation 
therapy. The surviving fraction following 
radiation could be a function of high D0/inherent 
radioresistance and/or the capacity to accumulate 
sublethal damage or recovery over a period of hours.
The maximum survival potential of a tumour cell, 
therefore, could be an important factor in clinical 
radiocurability. (9).
The more resistant types of human tumour e.g. 
gliomas do have significantly more intrinsic 
radioresistance to low doses than other types of 
tumour.(26,27,28).
Parshad et al completed experiments on the 
chromosomal radiosensitivity of 13 human tumours 
from diverse tissue origins and discovered that all 
the tumour cells displayed enhanced G2 chromosomal 
radiosensitivity, comnared to normal cells.(23).
The effect, therefore, which tumour 
radioresistance has on patient.survival is dependant 
upon the type of cancer present and the level of 
disease control.(6).
(2) Host Related Factors
(a) The Volume Effect
The complications in 'deep-seated’ tissues are 
dependant upon the volume irradiated, therefore, when 
large treatment volumes are needed to encompass known
or suspected disease, the clinical rsdioresistance 
of a tumour increases.
(b) Dose Limiting Normal Tissues.
The total biological dose of radiation given to 
a tumour is dependant upon the dose-limiting organ/ 
tissue within the treatment site and so, depending
upon the relevant normal tissue, a tumour might he said 
to he clinically more difficult to treat in one site than anot
(c ) Ps tho-ohys iological Factors.
These effect the tumour directly e.g. by 
increasing the number of hypoxic ceils in an anaemic 
state.
(d ) Host Defenses
T'-'is is unlikely to affect the clinical problem 
of radioresistance.
( f ) Technical Pact or.
These include error in dose delivery and 
geographical miss i.e. the need to encompass all the 
tumour.
Multiple Dose Fractions and Dose Survival Curves.
On a multifraction irradiation dose survival curve, 
after allowing for complete sublethal damage repair 
between doses, the slope will have an increasingly 
downward trend as the dose per.fraction decreases.
The dose oer fraction will eventually reach the 
zone where the majority of cell killing is due to 
single hit events and not the accumulation of 
sublethal damage. When the dose per fraction is 
small enough, the slope of the fractionated survival 
curve is determined by the single hit component of 
cell killing and this represents the limiting slope
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irrespective of further fractionation (17).
Repair of subcellul^r injury, regeneration, cell 
cycle redistribution and reoxygena.tion all 
contribute to differentials in fractionated dose 
response between various normal tissues and tumours. 
Studies by Withers examined fractionated dose 
responses of the three generic tissues types: Acute/
Early responding normal tissue, Slowly/Late 
responding normal tissue and Tumour tissue . (7). 
Regeneration
When radiation treatment is continued over 
several weeks, surviving stem cell regeneration is 
the most important contributer to the differential 
sparing of early responding tissues relative to both 
slowly responding normal tissues and, most of all, 
tumour tissue.
The onset of regeneration depends upon the 
development rate and severity of injury which, in 
turn, is dependant upon tissue kinetics and, to 
a lesser extent, dose given. The latency in the 
onset of regeneration of the surviving cells is also 
important and may last from days to weeks 
depending upon the tissue e.g. G.I. Tract - within 
a few days and the skin - within 3-4 weeks (7,17).
It is believed that the target cells for late 
seouelae do not display significant regeneration 
throughout the course of a conventionally fractionated 
regimen.
Tumours can accelerate their growth rate due to 
cytocidal effects of radiotherapy. Relay between 
initial radiation and the onset of regrowth is
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probably due to the proliferation kinetics of the 
tumour clonogens and to a certain extent, the size 
and delivery pattern of the dose. The onset of 
regrowth is slower after a set of multiple fractions 
than after a large single dose of radiation.
Repair of Cellular Injury
Early responding normal tissue do not disolay 
as large a capacity for cellular repair than late 
responding normal tissue (7). Late responding 
normal tissues determine the tolerance doses which 
are dependant upon the late responding tissue in 
question and the volume irradiated. This could be 
attributable to the fact that target cells for late 
effects have the ability to repair more subletnal 
damage tnan the target cells in acutely res conning 
tis-^es (7,o).
TLn^'-'E ratio of the Linesr-Ouacratic model 
describes the susceptibility of tissues to single 
and multihit killing with late responding normal 
tissues responding as though they were more 
susceptible to multihit mechanisms. The B/°< ra tio 
is a measure of tissue sensitivity to changes in 
size of dose oer fraction. Late responding normal 
tissues are characterized by larger values of B/o( 
than acute responding normal tissues (8,17).
There is no experimental evidence to suggest that 
tumour cells are capable of more recair of sublethal 
demange than normal cells, although some studies 
have shown that, due to hypoxia or low levels of 
cyclic AMP, tumour cells may have a reduced repair
capacity (10).
Repair of sublethal damage due to dose 
fracticnation should spare tumour cells to about 
the same extent as acutely responding normal 
tissues, but to a lesser extent than it spares 
slowly responding normal tissues.
Reoxygenation
Reoxygenation is not a factor in the response 
of acute or late responding normal tissues, although 
reoxygenation during a radiation treatment course, 
sensitizes the hvpoxic fraction of tumour cells (10).
Although the mechanism of reoxygenation is not 
fully understood, several factors may Play a part:
(1) feath of some of the tumour cell population 
will result in a reduction in oxygen consumption and 
the dead cells’ removal could reduce the average 
intercapillary distance.
(2) Loss of tumour substance may help to improve 
blood flow due to a reduction in tissue tension and
(3) an increase in vascularization may occur (3,11). 
Reoxygenation can account for the success of
fractionated radiotherapy relative only to single­
dose treatment. It cannot account for a 
favourable differential between normal and neoplastic 
tissue responses since normal tissues are usually 
well oxygenated (10).
Redistribution
The effect of redistribution is to reduce the 
probability that surviving cells will be in 
resistant phases of the cell cycle at times of 
subsequent doses of radiation (17).
The effect is difficult to assess in early
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responding normal tissues because it is overshadowed 
by the protective effect of regeneration.
The target cells for late sequelae are slow 
to oroliferate and so undergo little cell cycle 
redistribution during a multifractionation regimen. 
Late resoonding normal tissues are less sensitized 
by redistribution which, therefore, results in less 
severe late reactions for a given level of tumour 
control.
It is likely, but unoroven, that both normal and 
malignant proliferative tissues may self sensitize 
themselves by redistribution during clinical 
mult if r,;- ct ion regimens in a manner similar to the 
sensitization of tumours by reoxygenation. This 
would cause an increase in the therapeutic ratio 
obtained with dose fractionation by allowing the 
tumour clonogen population to ’ self-sensitize' itself 
in the absence of a similar effect in slowly 
resocndinm cells whose depletion leads to late injury.
There are two detectable phases through which 
a cell passes during a division cycle - mitosis, 
which is visible microscopically, and DNA synthesis 
which is detected by the uptake of radioisotope 
labeled DNA precursors. Between mitosis (M) and 
DBA synthesis (S) there is a gap (Gq) and after DNA 
synthesis, before the next mitosis, a second gap (Gp). 
(10,12,25).
Sinclair and Morton irradiated Chinese hamster 
cells at different cell cycle phases. They found 
that the most sensitive cells were in mitosis (M) or 
at the Gq:S ohase with the most resistant cells at the
late o ohas e and in the 'middle’ of the long Gq phases. 
(10,12) .
Slowly proliferating cells may stay in a 
radioresistant phase post irradiation but rapidly 
proliferating cells will redistribute themselves into 
more sensitive phases in time for subsequent dose 
f ra ct i ons.
Kmcer:" ractionation
//itners defined Hyoerf ra ct iona tion as the division 
of radiation treatment into smaller them conventional 
coses oer fraction without a h-'-yaae in the overall 
treatment duration. (7).
The aim of Kycerfrsctionation is to increase 
the therapeutic differential between late responding 
normal tissues and tumour tissues. Acute responses 
’would be expected to parallel tumour responses and 
so, if slowly responding tissues are treated to their 
t ole ranee by increasing the dose sufficiently, a cute 
normal tissue responses should be increased in parallel 
with an improvement in tumour control probability.
The rationale behind Hyperfraction-tion is that 
due to a larger repair capacity of sublethal injury, 
slowly responding tissues are spared more by reducing 
the dose per fraction, than are tumours. (7,14,15)*
The responses of acute responding normal tissues 
are increased, although they can be tolerated with 
good nursing care, and, if this is not possible, then 
an extension of the overall time would have to be 
introduced.
If cell cycle redistribution restored the surviving 
proliferative cells to the starting - more
9radiosensitive asynchronous state, then it would 
be more effective, in it’s sensitizing influence, 
if the doses per fraction were smaller and the 
fractionation intervals were more frequent. (7,14-)* 
Since reduction occurs in all cycling cell, no 
therapeutic gain will occur relative to normal 
epithelial cells which determine acute reactions.(14)• 
When the radiation dose is fractionated, 
sublethal injury is reoaired over a period of hours.
In low dose regions of cell survival curves, the 
majority of cell hilling is the result of single 
hits. The accumulation of sublethal injury has 
a low probability of causing cell death because the 
number of lethal lesions per cell is usually less 
than the lethal number (14,17).
Dose oer Fraction
The exact dose-response relationships for late 
responding normal tissues have not been measured 
over a dose range of 1-2 Gray. The dose range of 
the initial exponential region of cell survival 
curves is also uncertain.(21).
The biologic equivalence sought in the 
conventional and hyperfractionated regimens is in 
late - not acute - effects. Increased acute effects 
mav make it difficult to mive the acoropriate dose 
for eouivalent late effecos in exactly the same 
overall treataent time.
'fith hieher fractional doses, which reduce 
survival beyond the initial exponential region of 
a survival curve, accumulation of subietoal injury
/1Q* t s
subletna 1 da/cage after every larger fraction 'Tieans 
that extra dose has to be delivered in the next 
fraction to bring the average number of sublethal 
lesions per surviving cell back to the lethal 
threshold. Therefore, the total dose reouired 
to produce the same effect is increased when the 
number of fractions in this size range is increased. 
(12,14,17)•
Experimental studies have suggested that a basic 
difference exists between the survival curves of 
the target cells determining acute and late normal 
tissue effects. A difference which causes late 
resoonses to be more critically affected by changes 
in dose fractionstion.(14).
A well known clinical manifestation of this 
difference when changing to fractionation regimens 
with fewer, larger doses ^er fraction is the 
observation of large increases in late effect incidences 
with little or no change in acute effects. (12,14).
It is suggested that Hyperfractionation is 
advantageous, in that, when late damage is the 
limiting factor, it allows higher total doses to be 
given in a larger number of smaller fractions than 
usual.
Fractionation Interval
It is thought that sublethal damage repair in 
acutely responding normal tissues is achieved in 
3 hours.(7).
This may not be true for late effects tissues or 
for all acute effect ones. An ideal fractionation 
interval should be at least 6 hours to ensure tnat
suble oHdl repair is complete in the dose limiting 
19-1e nesoonding normal tissues • If repair is 
complete in acutely responding tissues (including the 
tumour) but not in the late resnonding normal 
tissue, the influence of the most important 
rationale for Hyperfractionation - fifferential 
Repair - is lost, or at least reduced.
The overall treatment time should be the same 
in Kyperfractionated and conventional treatment, 
although there are advantages and disadvantages 
to crolonsstion of treatment time.
The disadvantages are:
(1) the tumour cells have more time to proliferate 
therefore nahing ultimate cure less likely and
(2) it is inconvenient for the oatient and it is 
exn--ns ive .
The advantages are:
(1) it scares the acute reactions since compensatory 
proliferation in skin or mucosa accelerates at
2-3 weeks after starting an irradiation course,
(2) it permits adequate reoxyvenation to occur in 
tumours before the end of the treatment*
.(14,15).
Potential Thereceutic Gain.
The increase in tolerance dose for slowly 
responding late effects tissues has not been 
experimentally determined for doses of <T2.6 Gray for 
lung and this has produced inconsistant data.
If tumours show the same fractionation response 
as acutely responding normal tissues, the escalation
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is the do^e required fop an isoeffect (eoual fanour 
uOntrol probability) determined by using ano^/B ratio 
of 10 Gray would be -?87,
that is 2n x 1.08 Gy = n x 2 Gy.
So, if late effect tissues can tolerate a 15-257
increase in dose, when n fractions of 2 Gy are
replaced by 2n fractions, then the therapeutic gain
would lie between
1.15 = 1.065 and 1.2 5 = 1.16
1.08 1.08
ecuivslent to 2:0 increase in tumour effective dose 
of 6.5 - 16"- for the same tolerance dose in late 
responding tissues. (7 ).
The gain would be further increased if, the greater 
number of fractionation intervals and smaller doses 
per fraction, resulted in a greater response due 
to cell cvcle redistribution, with no change in 
slowly developing normal tissue responses.
The impact of Therapeutic Gain Factors of I.C65 - 
1.16 on Tumour Control Probability would depend upon 
the steepness of Tumour Control Probability curves.
In conclusion then, it is generally agreed that 
malignant tumours have a lesser repair capacity for 
sublethal damage and have faster proliferation kinetics 
than normal tissues, under steady state conditions.
Deacon et al, Fertil and Kalaise and Weichselbaum 
have suggested that, due to the vast diversity in 
the radiobiology of human tumour cells - with respect 
to fintrinsic radiosensitivity’ and ’post irradiation 
damage repair1, Hypsi’fractiona.ted treatment regimens may 
not be suitable for every malignant tumour type.
(9, 5,26,28) .
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It is therefore desirable to complete 
experimental studies on individual tumours wherever 
pos s ible.
Hyoerfractionation and Neuroblastoma
Wheldon et al suggested that neuroblastoma may 
be a suitable candidate for Hyperfractionation, 
although this has not, so far, been attempted 
clinically (33). The radiobiological rationale 
for Eyperfractionation in Neuroblastoma is based 
mainly on single dose cell capacity for the repair 
of sublethal damage as discovered by Wheldon et al (32). 
The extension, therefore, of the investigation to 
include solit-dose ana fractionated irradiation would 
aooear to be the next step.
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Chapter 111
THE TUMOUR SPHEROID MODEL
Cellular aggregates of animal cells have been 
used in developmental biology and experimental 
cancer research for several decades. As long ago 
as 1944, Holtfreter described a method he used 
to generate stable, spherical aggregates of 
embryonic cells. (1).
In 1959, Pabrowska - Piaskowska examined the 
'histo-formative capacities’ of cell aggregates 
of C3H mammary tumour and vaginal epithelioma 
cells, and discovered that there was a remarkable 
structural similarity between tumour cell aggregates 
and the original tumour tissue. (2).
In 1967, McAllister et al described a pronounced 
similarity between the cytological characteristics 
of the primary tumours, the respective colonies 
and the tumours induced by in vivo implantation 
of the cultured cells. It was also reported that 
the almost spherical colonies consisted of a 
central, necrotic area, surrounded by a run of 
viable cells with interspersed, degenerated forms. (3) 
Sutherland et al were the first to study the 
responses of cell aggregates to radiation therapy 
using Chinese Hamster V79 lung cells. It was 
because of their almost perfect spherical shape that 
the aggregates were called ’multi-cell spheroids’ or 
’multicellular spheroids’. (4,5)•
It was noted that the cellular aggregates bore 
a close resemblance to nodular structures observed 
in C3H mouse mammary carcinomas. These experiments
showed that a multi-component survival curve was 
generated when mammalian cells in the form of Lulti- 
cellular Tumour Spheroids (MTS) were irradiated.
The curve was seen to be similar to that reoorted 
for solid animal tumours and several types of human 
tumours and so multicellular tumour spheroids 
were henceforth considered as in vitro models for 
examining the basic biological properties of cancer 
cells in vivo (4,5).
Characteristics of hulticellular Tumour Spheroids. 
Growth of spheroids
The volume growth kinetics of IiTS are known to 
be similar to that of solid tumours. There are 
3 phases of spheroidal growth which are distinguishable 
The first phase is the initiation phase and is 
characterized by the aggregation of single cells to 
form small clumrs and t^en a period of geometric, 
exponential growth until the spheroid diameter is 
between 5C - 2CC un. (6,7,2).
At this point, the cell cycle distribution changes 
within the spheroid, resulting in an accumulation 
of resting cells at the centre of the spheroid and 
a sequestering of the proliferating cells at the
periphery. (8).
As the MTS increases in size, more diffusion 
gradients of nutrients and catabolites set in and 
it becomes a 2 layered solid, with an outer, well- 
nourished and proliferative 'crust1 and an inner, 
deprived and non-proliferative mantle . (6).
This leads to a progressive diminution of the
growth fraction and to a second phase of growth,
characterized by a linear expansion of the spheroid 
diameter with time. (8).
luring the second phase, the cell cycle 
distrioution starts to alter, towards an 
increasing accumulation of non—nroliferating cells 
in central regions of the spheroids. (9).
At a later stage, which is line characteristic, 
the ATS develops a central ’necrotic' core which 
continues to increase proportionally as the overall 
size increased. Central necrotic cells are 
observed occasionally at A-200 jim diameter and 
are clearly evident at JCC jam. (A).
Eventually the ATS, like solid tumours in vivo, 
are heterogeneous cellular masses with three layers 
- the outer, proliferative crust, the middle, viable 
but non-proliferative mantle and a central, necrotic 
core. (6).
Sutherland et al suggested that the fraction of 
cells in the intermediate zone increased as the
spheroid grew, which accounted for the reduction in
the growth fraction. (90 •
At later times of plateau and senescence, cell 
shedding of the ATS and cell packing in the 
interior may be appreciable.
These do not significantly affect the growth rate
during the initial and linear growth phases because 
if this were the case, then the growth rate would be
less than linear. (6).
In clinical oncology, it seems likely that the 
pattern of linear increase in diameter with time might 
also apply to 1 micrometastases' in vivo.i iu the period
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before the development of intratumoural blood supply.
When this occurs, the diffusion of metabolites and 
catabolites is no longer solely through 
the external surface of the solid aggregate and 
different conditions apply. (6).
As the spheroids enlarge further, their growth 
progressively slows down and the MTS reach a 
maximum diameter. (8).
Spheroids v:hose maximum diameter has been 
achieved, can be maintained in culture for several 
weeks with practically no increase in their volume, 
irrespective of however often the medium is 
replenished.
Folkman et al demonstrated that the same 
saturation in volume growth was obtained when 
spheroids were implanted into animals in such a way 
that vascularization of the implant, from the host, 
was prevented. (1C).
Landry et al developed a growth model for 
soheroids v/hich took into account parameters such 
as cell size, cell doubling time snd cell shedding 
r at e . (8).
Yuhas et al demonstrated a correlation (for 3 murine 
cell lines) between tumour growth rate and spheroid 
growth rate, while no such correlation could be 
demonstrated between tumours and standard monolayers. (^d) 
Structure of Spheroids
Yuhas and Li looked at 7 different tumour lines 
and discovered that the outer, proliferative crust had 
a constant thickness which was characteristic for each ^
cell line.
They discovered that, if the cell cycle times 
were the same, the tumour lines with the thick, 
proliferative crust grew faster than those with 
the thin, proliferative layers. (12).
Conger and Ziskin demonstrated that the 
mantle maintained a constant thickness and so 
the entire ’viable’ rim had a constant thickness as 
the diameter increased over the full range of 
linear growth. (6). Their findings that crust 
thickness was line specific and different for 
different cell lines supported the findings of 
Yuhas and Li.
Since the nutrient and oxygen concentration of 
the medium at the MTS surface is constant and if 
the metabolic rate is constant with time, it follows 
that a gradient of nutrients in, and catabolites 
out, will be established within the MTS.
If there is a nutrition or catabolite threshold 
level at which proliferation ceases, then it is 
easy to see why the proliferative crust thickness 
is constant.
Freyer and Sutherland completed experiments in 
dissociating EMT6/R0 MTS to produce 8 subpopulations 
of cells originating from a varying depth within 
the spheroid. (9).
The cells located further into the spheroid 
(50 - 100 Jim) usually remained viable and were 
capable of forming colonies. They were smaller 
in size than outer cells and no longer incorporated 
•^ H - thymidine into their DNA. The cells were not 
incapable of such incorporation but were dormant.
The cells located further than 100 from the 
spheroid surface were also arrested in their cell 
cyclQ progression, but, in addition, many of their 
inner region cells had a reduced viability and 
a markedly reduced ability to form colonies.
The cells located nearest the necrotic centre were 
apparently not far from cell death and lysis. (9).
It has been outlined previously that spheroids 
possess a histological structure similar to that 
of solid tumours as regards the distribution of 
vital and necrotic areas. This is also, at least 
partly true for the extracellular matrix.
Nederman et al identified similar matrix 
components such as giycosaminoglycans or collagen 
in tumour spheroids and their respective tumours. (13).
when the spheroid cells were grown as monolayers, 
the amount of synthesizing matrix materials appeared 
to be reduced or even absent.
This is an illustration that the degree of 
structural and functional differentiation in the 
primary tumour may be retained in spheroids rather 
than in monolayer cultures. (14).
Many recent publications on multicellular 
spheroids are concerned with the simulation of various 
tumour therapies, since the in vivo response of 
cancer cells to treatment may be reproduced in 
soheroids more closely than in conventional monolayer 
cultures .
Contact Resistance
The reaction of multicellular spheroids to ionizing 
radiation has been investigated most intensively and
O'l vo
one of the most interesting observations is the 
finding that some cells grown as spheroids are more 
resistant to ionizing radiation than the same cells 
grown as monolayer under otherwise similar 
conditions. (15). Sutherland and Durand 
suggested that this provided one possible mechanism 
for tumour radioresistance in vivo (16).
The 'contact effect’ or ’contact resistance’ is 
poorly understood. However, it has been suggested 
that it may be correlated with the occurrence of 
gap junctions and, with some restrictions, of 
electrical coupling between cells. (17).
The activity of adenylate cyclase in coupled 
cells cultured in vitro as multicellular tumour 
soheroids falls to a level much lower than under 
any other culture conditions. (18).
Variations in CAMP, which are capable of 
modulating the oermeability of gap junctions, can 
modify contact resistance.
Changes in Ca^+ and H + ion concentrations, can 
also alter the permeability of gap junctions. (17).
Although the molecular mechanism of the contact 
effect is still unknown, it has been hypothesized 
that the radiocurability of tumour cells may be 
enhanced by manipulation of CAMP, H + or Ca^ + ions, 
using aporopriate drugs. (17).
The local eradication of a tumour in vivo by 
irradiation is influenced directly by the 
radiosensitivity of the cell population, the number 
of viable cells in the tumour at the time of treatment, 
cellular hypoxia, radiation quality, dose and dose
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rate.
Other factors which may influence observed tumour 
responses are host—tumour interactions (immunological 
or other} effects of the radiation on the vascular 
supply and the number of ‘surviving’ cells 
required to regrow and thus re-establish the tumour. 
Use of Snd-roints
A variety of techniques have been developed 
to quantify the effects of ionizing radiation on 
tumour cells. Eurand examined the use of a variety 
of end-points which could be intercompared when using 
MTS as an in vitro tumour model system. (19). The 
end-pcints examined included growth delay and 'cure'.
Growth delay is conventionally defined as the 
time taken for the median volume of each individual 
MTS to reach some multiple of its original volume 
(e.g. X1C) .
Multicellular tumour spheroids are considered to 
have been 'cured' i.e. all the clonogeric sterilized, 
if they fail to regrow - with regrowth defined as 
reaching some multiple of their volume - by some 
specified time. (e.g. one month).
Regrowth curves may theoretically allow 
estimation of cell curvival in situ as long as the 
surviving cells' growth continues as in the 
un-irradiated case. If this is the case, then 
regrowth curves may be interpreted as simple 
displacements of the control growth curve, with the 
displacement providing a measure of the magnitude 
of cell kill assumed to have taken place. 
Extrapolation of the regrowth curve to zero time
yields an estimate (VE ) of the 'effective volume' 
from which the sphenoid appoars to have regrown, 
ihis is to s a y , it represents the volume of viable 
cells following treatment. The ratio Ve  to the 
measured volume Vq (which represents the volume of 
all the cells initially present) provides a 
measure of the cellular surviving fraction (S) 
immediately following treatment. (20). Some 
pitfalls in this type of analysis have recently been 
pointed out by Moore et al. (21).
Experimental Radiotherapy of Tumour Spheroids
Rofstad et al studied the radiation response of 
MTS initiated from a human melanoma xenograft using 
cell survival growth delay and spheroid cure as end­
points. (22)
The relationship between these end-points was 
analysed and the radiation response of the spheroids 
was compared with the parent xenograft.
The L'o values calculated from spheroid cure curves 
were similar to t^.ose of the cell curvival curves 
measured in soft agar.
The specific growth delays, as well as the To 
values, calculated from cure curves were similar 
for spheroids and tumours, when the data for the 
latter was corrected for the presence of hypoxic 
cells.
Rofstad et al used 5 melanoma cell lines and 
discovered that the cell survival curves for cells 
irradiated after disaggregation of the spheroid were 
equal to those previously reported for cells from 
disaggregated tumours of the same melanomas. That
is to say, that the cellular radiosensitivity was 
the same whether the cells were grown as spheroids 
in 1 iquid — overlay culture or as solid tumours in vivo 
i.e. Contact resistance was not seen for those cell 
lines. (23).
Evans et al set up experiments to determine 
whether a parallelism existed between the clinical 
behaviours of specific human tumour types - 
neuroblastoma and melanoma - and the biological 
behaviour of the same tumour types grown as MTS. (24). 
The growth delay data correlated with the clinical 
response of the tumours.
Evans et al concluded that MTS provided an in vitro 
tumour model system which was amenable to the study 
of common radio-biological end-points including cure, 
regression and cell-survival which was likely to be 
of clinical relevance.
Although neuroblastoma is a clinically 
radioresnonsive neoola.sm, it is fatal in three out 
of every four cases, due to it’s pattern of early 
dissemination. (25).
Micrometastases are often present at the time of 
diagnosis and because tumour spheroids in vitro 
are considered to be an appropriate model for 
avascular micrometastases in vivo, it would seem 
appropriate to use tumour spheroids as an in vitro 
model for the treatment of neuroblastoma with T.B.l.
Materials and Methods 
Origin of NB1-G
NB1-G cell line was obtained by growth in 
monolayer culture of cells released by enzymatic 
disaggregation of a human tumour xenograft 
originated from tumour fragments obtained by 
surgical excision of a stage IV abdominal 
neuroblastoma in a 2 year old boy.
In culture, NB1-G cells synthesize catecholamines, 
have neurosecretory granules visible by electron 
micros cony and an aberrant but identifiable human 
karyotype. In situ DNA hybridization studies have 
revealed the presence of multiple copies of the 
human oncogene N-MYC (1).
Origin of 1MR-52
1KR-32 was obtained from a Stage IV abdom'.nal mass 
in a 13 month old boy and was mechanically 
disaggregated and set down in flasks i.e. a primary 
culture.
1MR-32 is an established cell line (1967), it is 
hyoerdioloid and consists of a mixed culture of at 
least 2 morphologically distinct cell types.
The catecholamine synthesis of E-IR - 32 is not 
known. Heurosecretary granules have not been reported.
The second cell type are found in minute numbers 
and are relatively large, well-spread fibroblast like 
cells. (2) The cell line shows several features 
characteristic of human neuroblastoma including the 
existence of chromosomal Homogeneously Staining Regions
(HSRs) and an amnlified cooy number of the human 
proto-oncogene N-MYC (3).
Monolayer Culture.
NB1-G and 1MR32 cells were plated into 75 cm2 
flasks containing 20 mis of medium (MEM) with foetal 
calf serum (10%) at a concentration of 5 x 105 cells. 
The flasks were then incubated at 37°C in an 
atmosohere of 5% CO2 at 100% humidity.
Spheroid Culture
Monolayer cultures of NB1-G and 1MR-32 were 
trypsinized, cell suspensions were obtained and, 
using the »agar-underlay' method, were seeded to 
initiate MTS production. (4) In each 25 cm2 flask, 
base-coated with 1% Noble-agar, 10^ cells were seeded 
into 5 mis of medium (MEM) containing 10% foetal calf 
serum. Incubation took place in a humid atmosuhere 
(100%) at 37% with 5% CO2 content. After 2 - 3  
days, the Spheroids were large enough to be 
individually ’harvested' with a Pasteur pipette.
The spheroids selected those with a diameter of-*■ 250 JJ'A 
- were transferred individually to agar coated wells of 
24 well test plates (Linbro). The plates were 
incubated as described and 0.5 mis of medium was added 
weekly to each well.
Determination of Spheroid Growth Curves.
Using an automated image analysis scanning system 
(see Twentyman 1982), thrice weekly measurements of 
the cross-sectional area of the individual MTS were 
used to determine the growth of MTS. (5)*
It was assumed that the MTS were spherical and their 
cross-sectional measurements were converted to
estimates of volume. By plotting the median volume 
value for each MTS against each day of measurement 
for each experimental group, spheroid growth curves 
were obtained.
Irradiation Procedures
The MTS were placed in test-plates for the 
irradiations which were carried out using a Co^C 
treatment unit. The dose rate was approximately 
1 Gy/min and to ensure the maximum deposition of 
energy per well, a perspex ’build-up' was used. (, I c- 
Single Dose Studies
The single dose studies were carried out to 
evaluate the simple cose radiosensitivity of NB1-G 
and 1MR-3? spheroids as assessed by the growth delay 
end-point. The doses ranged from 50 cGy to 300 cGs 
increasing in %C c.Gv instalments.
Split Bose Studies
The Split-dose Studies were carried out to 
determine the split-dose ra.diosensitivity of BB1-G 
and 1MR-32 spheroids using the growth delay end. point.
The dose range was between. 2 x 25 cGy and 2 x 100 
c G y with the time interval between the two doses at 
6 hours.
The snlit-dose method was employed to investigate 
whether NB1-G and 1MR-32 spheroids we re capable of 
repairing sublethal damage.
Fractionated Treatment Regimens
Using the linear-quadratic model (with q  = 3 G,-) 
a series of treatment regimens were designed which 
were calculated to be isoeffective for late responding 
normal tissues (see Appendix).
NB1-G
Two sets of regimes were used on two separate 
occasions. One set of regimens (A) was calculated 
to be late - responsive - isoeffective to a single 
dose treatment of 2.3 Gy. The other set (B) was late- 
resDonsive - isoeffective to a single dose treatment 
of 4 Gy.
Each set of regimes consisted of five isoeffective 
schedules ranging from one to eight treatment fractions 
The two sets of regimes may be regarded as 
corresponding to two different 'effect levels'
(A £E 1 ^ 2.5 Gy, B E  1 x 4 Gy) for damage to late 
responding normal tissues. Table 1 contains all the 
details of the schedules.
1MR-32
The treatment regime was designed to be 'late- 
responsive - isoeffective' to a single dose of 2.5 Gy. 
Five different isoeffective regimes were used, ranging 
from one to eight treatment fractions. These are 
summarized in Table 2.
It was considered necessary to have an inter­
fraction interval of at least 6 hours and so the split 
and fractionated doses were given twice daily.
Estimation of Growth Delay
Using the MTS median growth curves, the growth
delay value for each experimental group was 
determined.
Estimation of Cell Survival from Regrowth Curves 
If it is assumed that regrowth delay is mostly 
due to cell sterilization, and that irradiation has 
little effect on the growth kinetics of the 
surviving cells, then by back extrapolating the 
regrowth curves to zero time, an estimation can be 
made of median cell survival. (see o Ibl )
).
'Proportion c u r e d '
MTS.were considered to have been 'cured'
(i.e. all the clonogenic cells sterilized) if they 
failed to regrow (defined as reaching at least 3 X 
original volume) by 1 month following treatment.
In prsctice there was a clear demarcation between 
regrowing and non regrowing MTS at the time. The 
'proportion cured' was then evaluated as the fraction 
of non-growing MTS relative to the total number of 
MTS originally present in the treatment group.
TA-LE 1
Normal tissue 
effect level
Fraction 
Numb e r
Dose/
Fractionation
(Gy)
Total 
time 
(bays)
Total
dose
(Gy)
A 1 2.50 0 2.50
2 1.52 0.25 3.04
4/* 0.89 1.25 3.566 0.63 2.25 3.78
8 0.49 3.25 3.92
B 1 4.00 0 4.00
2 2.53 0.25 5.06
4 1.54 1.25 6.16
6 1.13 2.25 6.78
8 0.90 3.25 7.20
TAELE 2
Treatment 
s chedule
Fra ction 
Number
Dose/
Fractionation
(Gy)
Total 
time 
(days)
Total
dose
(Gy)
A 1 4.00 0 4.00
B 2 2.53 0.25 5.06
C 4 1.54 1.25 6.16
D 6 1.13 2.25 6.78
E 8 0.90 3.25 7.20 j 
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rIS CUSS 1 ON OF RESULTS.
NB1-G Single Dose Irradiation 
Spheroid Growth Curves
The UB1-G MTS in test plates were irradiated 
with a single dose of 50, 100, 150, 2C0, 250, 300 
or 350 cG -■ •
In fig.l it can be seen that the unirradiated 
spheroids grew exponentially with doubling times 
of^-2.5 days until a diameter of 800 - 1,000 ^ JM was 
reached after which growth slowed with a progressive 
lengthening of the doubling time.
Irradiated spheroids exhibited either a static 
phase, or a regression phase (dose dependant) which 
was followed by a recovery of the growth curve to 
a pattern similar to that for unirradiated spheroids.
The exponential portions of the regrowth curves 
were, to a reasonable approximation, parallel to 
each other and to the corresponding portion of the 
control growth curve.
Very few spheroids failed to regrow following 
irradiation in the dose range used (50 - 330 c G v )  
so that no ’cure correction' was necessary to the 
growth date.
Growth Delay
It can be seen from the growth delay curve in fig.2 
that, after an initial region of shallow slope, the 
curve steepens as the dose is increased.
NB1-G Split Dose Irradiation
Spheroid growth curves
The NB1-G MTS in test plates were irradiated with
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a split dose of 2 x 25, 2 x 50, 2 x 75 or 2 x 100 cGv .
/
In fig.3 the control growth curve follows a 
characteristically exponential form (volume doubling 
time■*'2 - 3 days) until a diameter of >-800 - 1,000^JM 
after which growth slows progressively.
Growth curves for irradiated MTS displayed a static 
or regression phase before resumption of growth with 
growth curves becoming parallel to those of controls.
The lateral displacement of irradiated from control 
curves is seen to increase progressively with dose.
Growth Belay
Growth delay as a function of total dose is 
graphed in fig.4 and it can be seen that there is an 
initial region of shallow slope which steepens as the 
dose is increased, tlhen the growth delay curves for single 
and split dose (fig 2 & 4) are compared, it can be seen 
^ that there is no significant difference between the 
2 curves, indicating no sparing effect of dose 
fractionation as evaluated in terms of growth delay.
Cell Survival Curves
Fig.5 shows derived cell survival curves for both 
the single and split dose experiments whose growth 
delay curves are graphed in fig.2 and 4.
As may be seen, both survival curves are nearly 
exponential in form with little evidence for 
quadratic curvature, and with only small shoulders 
apparent. There is also little indication for a 
biphasic break in the curves as would occur if a 
significant proportion of the clonogenic cells of 
the spheroid were hypoxic.
The split dose data is consistent with negligible
capacity for the accumulation of sublethal damao-e. 
No significant repair capacity has been found for 
NB1-G human neuroblastoma MTS subjected to 2 doses 
of radiation in the total dose range 50 — 350 <G'
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riSCTmSIOM OF RESULTS
1MR-52 Single Pose Irradiation 
Spheroid Growth Curves
The MTS in test plates were irradiated with 9 
single dose of 50, 100, 150, 200, 250, 300 .oGy.
Fig.6 is representative of the growth curves 
obtained for control and irradiated MTS.
The control growth curve displays a characteristic 
exponential growth pattern, until a volume of 800 JJK 
- 1,000 JJK per spheroid is reached. Thereafter, 
growth slows with increasing size. The growth 
curves for the irradiated MTS show a progressively 
perturbed pattern as the dose is increased. At 
higher doses, a static or regressive phase is 
observed, before growth is resumed, usually 
becoming parallel to the control curve.
Growth Pelsv
A 3 can be seen from fig. 7 the growth delay curves 
have an initial region of shallow slope which then 
steepens with increasing dose. Each separate 
symbol is representative of a separate experiment to 
ensure the reproducibility of the results.
Survival Curves
The survival curves calculated from fig.7 are 
graphed on fig.8. Each symbol on the graph 
corresponds to the same symbol on the Growth Pelay 
Curves . As can be seen, the calculated survival 
curve appears to have an initial shoulder - and then 
became approximately linear as the dose is increased.
TIME 
(DAY 
S3
79
l O A  O O l
>0-
co-
o~
CO CJ KJ K) - I
o  Ui o  w  o  ^
n
o
IM
R
-32 
SINGLE 
DOSE 
FIG 
6
TOTAL 
DOSE 
C 
G
yD
I
C S A V O D  0 L X 
X
IM
R
-32 
SINGLE 
DOSE 
- 
G
RO
W
TH 
DELAY 
FIG
'•81
S B o ]
I
00
► ■
►II
£
73
I
CO
JO
O  
5> 
r~02 
oz
^ O O
Gnj= m n i
X  O  
m
I
CPc
<
£
c
<m
cn
O
CO
TIM
E 
C DAYSD
'82
00 A
GO
"O
01
X
O S UI K3
o  m o  w o
n
o
o
-o
S3
C S A V C D O L x
A
IM
R
-32 
SPLIT 
DOSE 
- 
G
ROW
TH 
DELAY
f84
S 6 o l
.00
I
*
k)
I
u
o
r\
o•<
IM
R-32 
SPLIT 
DOSE 
- 
SURVIVAL 
CURVES
1MR-52 Split Lose Irradiation 
Spheroid Growth Curves
The MTS in test olates were irradiated with 
split doses of 25, 50, 75 and ICO cGj with a 6 hour 
interval between the two irradiations.
Fig.9 demonstrates the growth curves obtained 
from the control and irradiated MTS. The control 
growth curve displays a characteristic growth 
pattern until a volume of 800yUM - 1, 000 JJM per 
spheroid is reached. The growth rate then slows, 
with increasing size. The lateral displacement 
of irradiated from control curves is seen to increase 
progressively with dose.
Growth relay
, lv * -
The growth''curves obtained from two experiments are 
graphed on fig.10 The two symbols represent two 
separate experiments.
Survival Curves
The survival curves are graphed on fig.11. The 
two survival curves appear to indicate the presence 
of a shoulder which would imply that 1MR-32 spheroids 
has an a.bility to accumulate and repair sublethal 
d a m a g e .
NBI-G Hyperfractionation.
Spheroid Growth Curves
hedian regrowth curves following treatment are only 
available for all treatment groups in the case of 
regimes, late-effect equivalent at effect level 
A ( 1 1  x 2.5 G y ) At effect level B ( =  1 x 4- Gv) the 
high values of 'proportion cured' mode definition of 
median regrowth curves impossible in most cases, 
results for effect level A are nresented in fig.i2 
This shows a progressive lateral displacement of 
regrowth curves with increasing total dose, the 
doses delivered by the fractionation regimes 
indicated (See Table 1) In most cases, the regrowth 
curves returned to become parallel to the control 
curve ‘ .
(6).
Growth Belay
B i g . s h o w s  (for regimes at effect level A) the 
increase in regrowth celay as a function of total 
cose delivered by the various regimes. (See Table 1) 
Regrowrth delay is seen to have a distinct dose-respons 
relationship, with upward curvature.
B i g . 14- displays the regrowth delay curve for 
irradiated RTS as a function of fraction size.
(Bata available for level A regimes only). This 
delay obtained decreases with increasing fraction size
Survival Gurves
The regrowth curves (at effect level a) generally 
showed a return to parallelism with control growth 
curves and therefore satisfied the condition for
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for estimation of cell survival in situ by back- 
extrapolation of regrowth curves. Fig.15 shows
estimated cell survival as a function of total dose- 
delivered by various regimes. (See Table 1). As can 
be seen, the responses of NB1-G MTS were dependant 
upon the total dose given.
Fig.16, shows the estimated cell survival as 
a function of fraction size and it can be seen that 
as the fraction size increased, the log cell kill 
decreased.
Proportion Cured.
In this case, results are available for both 
effect levels A and B. In fig.17, ’proportion cured’ 
has been plotted as a function of total dose 
delivered on the various regimes. (See Table 1)
Fig.18 displays ’proportion cured’ for irradiated 
MTS as a function of fraction size, for regimes 
administered at effect levels A and B.
1MR-52 Hyperfractionation 
Spheroid Growth Curves
~i 1 ■■ ■ -  - -
Fig.19 shows growth curves for control and 
irradiated MTS. The control growth curves, exhibit 
a characteristic exponential growth pattern, until 
a volume of 800JJM - l,000yUM per spheroid is reached. 
Thereafter growth slows with increasing size. The 
growth curves for the irradiated MTS shows an 
increasingly disturbed pattern as the dose is increased. 
At higher doses, a static or regressive phase is 
observed, before growth is resumed, usually becoming
parallel to the control curve.
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Growth relay
The growth delay curves for two separate 
experiments are graohed in fig.20 as a function of 
the total dose given on the various regimes. Fig.21 
shows the two growth delay curves graohed as a 
function of fraction size. Since the treatment 
regimes were calculated to be isoeffective for late- 
responding normal tissue, the lack of any obvious dose- 
deoendance implies that the regimes appear to be 
isoeffective for loR-32 spheroids also.
Survival Curves
The surviving fraction for each exoerimental group, 
as a function of total dose, as calculated from back - 
extraoolation of regrowth curves is graohed on fig.22. 
The surviving fraction as a function of fraction size 
is graohed on f i g.23 and they similarly show little 
deoendance on total dose and fraction size respectively. 
Proportion Cured.
Fig.24, shows proportion cured (Pc) graphed as 
a function of total dose and f i g.25 shows proportion 
cured graohed as a function of fraction size. It 
would apoear from both graphs that the 1MR-32 spneroids 
were about equally affected by the alternative 
schedules. This implies that.IMR—32 spheroids 
responded similarly to each of the different regimens 
chosen to be isoeffective for late responding normal 
tis sues.
DISC~TPSION AND CONCLUSIONS
In principle, clonogenic survival curves may be 
deduced from tumour regrowth data by extrapolation 
of regrowth curves to zero time. Previously, these 
deductions have been attempted to obtain ’in situ’ 
survival curves for experimental tumours irradiated 
in v i v o , but, the analysis in that situation is 
complicated by the existance of the tumour bed 
effect, possible immunological responses, tumour 
infiltration by host cells, the limited proliferation 
potential of ’doomed cells’ and the difficulty of 
obtaining accurate measurements of the regrowing 
tumour over an adequate range of sizes. (1).
The problem in spheroids is simpler, in that, the 
tumour bed effect, and host cell and immunological 
effects, are necessarily absent in vitro. It is 
feasible to make observations over a wide range of 
sizes and - at least in the present spheroid lines - 
doomed cell proliferation evidently does not sub­
stantially influence growth.
When looking at the survival curve for single dose 
irradiation of NB1-G spheroids, it can be seen that 
it is nearly exponential in form, with little 
evidence for quadratic curvature, and with only a 
small shoulder apparent. There is also little 
indication for a biphasic break in the curves, which 
would occur if a significant proportion of the 
clonogenic cells of the spheroid were hypoxic.
It can be interpreted that the derived survival curve
is representing the radiosensitivity of a well- 
oxygenated. neuroblastoma line, which has little 
capacity for accumulation of sublethal damage. Due 
to the fact that the cells were irradiated as spheroids 
the response includes any contribution made by 
’contact resistance’ and may be representative of 
the radio-sensitivities of similarly sized 
micrometastases in viv o .
The results indicate that NB1-G cells grown as 
spheroids are quite radiosensitive, being less 
resistant than the majority of mammalian cell lines 
grown in monolayer culture. (2,3).
The NB1-G spheroids have a Dq value of 17 cG'y 
which is about average for human neuroblastoma 
cell lines whose radiosensitivity in cultre has been 
reported. (4)•
These results are broadly consistent with other 
reports which indicate that neuroblastoma cells 
in vitro, are relatively radiosensitive and may have 
little or no capacity for cellular repair. (4,5).
Several studies, however, have appeared on the 
single dose radiosensitivity of human neuroblastoma 
cells in monolayer (4,5,6) or as MTS (5,7,8).
They reveal a significant heterogeneity in the 
Ija vitro radiosensitivity of human neuroblastoma cells 
with Do values ranging from 66 - 155 cGy.
Single dose irradiation studies on 1MR-32 spheroids 
imply a significant shoulder on the underlying cell 
survival curve. The Dq value obtained is close to 
1 Gray, which is larger than is seen for the majority 
of human neuroblastoma cell lines whose
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radiosensitivity in culture has been reported. (9)•
The results reported here are consistent with the 
interpretation that 1MR—32 cells grown as spheroids 
possess a significant capacity for repair of sub- 
lethal damage.
Division of a radiation dose in the range 150 - 
350 'cGy into two equal fractions spaced 6 hours apart 
seemed to render that NB1-G spheroids more sensitive 
to radiation than those exposed to single doses.
This result could be explained in terms of cellular 
redistribution throughput the mitotic cycle but is 
within experimental uncertanties in the data. There 
has been no evidence found for any substantial 
interfraction repair capacity of these MTS. (10)
It has been proposed that a systematic difference 
may exist in the repair capacities of tumour cells 
and target cells in normal tissues and that a 
therapeutic advantage might result from the use of 
small doses per fraction (Hyperfractionation) by which 
normal tissues should be preferentially spared. (11,12)
No significant repair capacity was found for NB1-G 
spheroids subjected to one or two doses of radiation 
in the total dose rang 50 - 330 cGy. which could be 
taken as providing a radiobiological rationale for the 
use of hyperfractionated treatment schedules in the 
adjuvant radiotherapy of neuroblastoma for which the 
target micrometastases may have similar 
radiobiological properties to MTS in vitro.
The split dose irradiation response of the 1MR-32 
spheroids appears to indicate the presence of a 
shoulder, which implies that 1MR-32 spheroids had an
ability to accumulate and repair sublethal damage.
The fact that 1MR-32 cells grown as spheroids possess 
a significant capacity for repair of sub-lethal 
damage which leads to relatively inefficient cell 
killing when radiation is given as multiple small 
fractions. The role of other factors 
(e . g . redistribution, repopulation, reoxygenation) 
cannot be excluded, however.
The use of hyperfractionated radiotherapy on 
NE1-G spheroids was designed to test the hypothesis 
of an exploitable difference in the radiobiological 
properties of neuroblastoma MTS relative to late 
responding normal tissues. The treatment regimes, at 
each effect level were calculated to be equivalent in 
their effects on late-responding normal tissues.
If NB1-G MTS haathe same properties as these normal 
tissues, the regimes should also have been equivalent 
on their effects on the MTS.
By each end-point, radiation damage to NB1-G MTS 
increased with total dose, regardless of how it was 
delivered. Since higher doses could be delivered by 
using smaller fractions (i . e . utilizing the high 
tolerance to small fractions of late-responding normal 
tissues) regimes using smaller fractions were more 
effective. This can be seen in fig.13 for effect 
level A and fig.17 for effect levels A and B, where 
regrowth delay and 'proportion cured' are plotted as 
functions of fraction size. The growth delay data 
was not available for effect level B because at the 
higher effect level, there were too many cures for 
definition of growth delay.
In general, these results support the superior 
effectiveness of hyperfractionation used to treat 
tumours whose cells have low capacity for repair of 
sublethal damage.
As can be seen from fig.16, there is a lateral 
displacement of the 'proportion cured' versus dose 
curves for effect levels A and B. Without this, 
the upper curve would have been a smooth continuation 
of the lower. The effect is small and is readily 
explained by the (accidental) difference in spheroid 
sizes in the two separate experiments.
However, each experiment considered independently 
yields the same conclusion, viz increasing 
proportion cured with increasing total dose.
When taken together, the NB1-G results provide 
encouragement that hyperfractionstion should be 
a useful strategy in the radiation therapy of at 
least some human tumours.
The results obtained from the use of hyperfraction­
ated radiation on 1MR-32 spheroids differed to those 
obtained from the NB1-G spheroids. When the 1MR-32 
cells were grown as spheroids, they seemed to possess 
a significant capacity for the accumulation and 
repair of sub-lethal damage. This leads to 
relatively inefficient cell killing when radiation is 
given as multiple small fractions although the role 
of other factors such as redistribution, 
repopulation and regeneration cannot be excluded.
The experiments on 1MR—32 neuroblastoma cells grown 
as MTS, suggest that the MTS respond to changes in 
fraction size in the same way as would be anticipated
for Iste-responding normal tissues.
By each end-point, radiation damage to 1MR-32 MTS 
did not appear to increase or decrease with increasing 
dose .
Although higher doses can be delivered by using 
smaller fractions, regimes using smaller fractions 
did not appear to be any more effective than regimes 
using larger fractions. This can be seen in fig.20
When the 'proportion cured' data was plotted as 
a function of fraction size, it was apparent that 
fraction size did not have any effect upon the 
proportion of 1MR-32 spheroids which were cured.
Each experiment, when looked at individually 
provides the same conclusion - the radiation regimes 
calculated to be isoeffective for late-responding 
normal tissues were also isoeffective in the treatment 
of 1MR-32 spheroids.
The clinical implication of these results is that, 
should some micrometastases behave similarly to 
1KR-32 spheroids, the use of multiple small fractions 
(hyperfractionation) would not necessarily result in 
a therapeutic advantage.
It should be noted that the results do not imply 
any disadvantage of hyperfractionation, only that all 
regimens with the same effect on late-resoonding 
normal tissues would have similar effects on the 
tumour. 1MR-32 may, however, be untypical of 
neuroblastoma cell lines in this respect.
10
OVERALL CONCLUSION
It seems plausible, on the basis of these results, 
that hyperfractionation would not be a universally 
advantageous strategy, but one whose efficacy is 
likely to depend on being able to select appropriate 
tumours for this form of treatment.
Further work is necessary to establish the 
generality of the excected advantage of 
hyperfractionation, even in laboratory models.
o\
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APPENDIX
In calculating total doses to make alternative 
fractionation regimes isoeffective for damage to late- 
responding normal tissues, the linear-quadratic model 
was utilized. This model assumes that gross effects 
of radiation are attributable to the sterilization of 
clonogenic 'target cells' in the tissue, whose
sterilization is responsible for the observed effects.
The target cells have a dose-response curve for 
clonogenic survival which is linear-auadratic in dose. 
The level of effect, denoted E, will also then be 
quadratic in dose, and proportional to number of 
treatments.
Viz E = N (cK d + pd2 ) (1)
Where d is dose Der fraction, N the number of
treatments given and ^  and p are parameters
characteristic of the tissue concerned. Two treatments 
utilizing different fractionation regimes (Ni, d*, ) and 
(Nt2, d 2 ) will be isoeffective for damage to that tissue
if their effects (Eq and E2) are the same.
Viz for equivalence,
Nq (o<dq + Bdq )• = N2 ( d2 + pd2 ) (2)
dividing through by p gives
Ni (g  d]_ + d22) = N2 d2 + df) (3)
The fraction size for regime 2 such that N2 fractions 
will have the same effect as regime 1 is given by the 
solution of the quadratic equation in d2 i.e.
—  <=< +  / / c k  )'+ + 4N| /c< dq + d^ Fj
d2 = B J ( B /  Na. V B_____________________ (4)
2
Hence doses on different regimes can be calculated 
to give equivalent effects on a tissue if itsck_ ratio 
is known. Values of the e s t i m a t e d ^  ratio for 
various normal tissues have recently been collated by 
Withers et al (7) and by Fowler (8) (See Materials 
references). Most late-responding tissues are found 
to have an ratio dose to 3 GY. Equation (4) with
F
3 GY, was used to calculate doses isoeffective for
P
damage to late-responding normal tissues. These 
regimes are specified in Tables 1 and 2.
